论文部分内容阅读
目的:观察国产粒细胞刺激因子(立生素G-CSF)在恶性肿瘤病人化疗过程中预防和治疗粒细胞减少的疗效。方法:240例病人,分为3组。第1组61例,化疗前WBC<4.0×109·L-1。用G-CSF3-5μg·kg-1·d-1,至WBC升至正常范围维持一周后开始化疗,化疗结束后,24-48h,给予G-CSF,连用7-14d;第2组,81例,既往有因化疗而WBC减少史,该次化疗前WBC正常范围。化疗结束后24-48h应用G-CSF,连用7-14d,剂量同1组;3组,首次化疗病人,98例,WBC正常范围,化疗结束后,每2天查WBC一次,当WBC<4.0×109/L时,开始应用G-CSF。结果:第1组7d内WBC减少者18例,14d仍未升至正常者8例;第2组分别是19例,5例;第3组分别是70例,23例。第1,2两组与第3组相比,其WBC降低例数明显减少(P<0.01),住院天数也明显缩短(P<0.01)。结论:国产G-CSF能够预防和治疗恶性肿瘤病人化疗阶段的粒细胞减少。
Objective: To observe the efficacy of domestic granulocyte-stimulating factor (G-CSF) in the prevention and treatment of neutropenia in the chemotherapy of malignant tumor patients. Methods: 240 patients were divided into 3 groups. The first group of 61 cases before chemotherapy WBC <4.0 × 109 · L-1. Chemotherapy was started one week after the WBC rose to the normal range with G-CSF3-5μg · kg-1 · d-1. G-CSF was administered for 24-48h after the end of chemotherapy and continued for 7-14 days; Group 2 81 For example, there is a history of WBC reduction due to chemotherapy, and the normal range of WBC before chemotherapy. G-CSF was administered 24-48h after chemotherapy, once daily for 7-14 days, with the same dosage as group 1. In the three groups, the first chemotherapy patients, 98 cases, the normal range of WBC, WBC once every two days after chemotherapy, × 109 / L, began to apply G-CSF. Results: In the first group, there were 18 cases of WBC reduction in 7 days, 8 cases of which did not rise to normal in 14 days. The second group were 19 cases and 5 cases, the third group were 70 cases and 23 cases. Compared with the third group, the number of WBC decreased significantly (P <0.01) and the number of days of hospitalization significantly shortened (P <0.01). Conclusion: Domestic G-CSF can prevent and treat neutropenia during chemotherapy in patients with malignant tumor.